Merck & Co’s TROP2 Partner Trumpets Phase III Success In TNBC
Kelun Planning China Filings
Merck & Co's antibody-drug conjugates pact with Kelun is progressing well and the lead candidate of the pact, the TROP2-targeting candidate codenamed SKB264/MK-2870, has significantly improved progression-free survival in triple-negative breast cancer patients in a late-stage trial in China.
